BR112022018251A2 - Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma - Google Patents
Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesmaInfo
- Publication number
- BR112022018251A2 BR112022018251A2 BR112022018251A BR112022018251A BR112022018251A2 BR 112022018251 A2 BR112022018251 A2 BR 112022018251A2 BR 112022018251 A BR112022018251 A BR 112022018251A BR 112022018251 A BR112022018251 A BR 112022018251A BR 112022018251 A2 BR112022018251 A2 BR 112022018251A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapy
- nirogacestat
- combination therapy
- bcma
- bcma targeted
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 229950001637 nirogacestat Drugs 0.000 title abstract 3
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title abstract 2
- 238000002626 targeted therapy Methods 0.000 title abstract 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
- 208000023761 AL amyloidosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000011748 cell maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018251A2 true BR112022018251A2 (pt) | 2022-11-08 |
Family
ID=75396879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018251A BR112022018251A2 (pt) | 2020-03-13 | 2021-03-12 | Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (enExample) |
| EP (1) | EP4132515A1 (enExample) |
| JP (2) | JP7781764B2 (enExample) |
| KR (1) | KR20230009873A (enExample) |
| CN (1) | CN115916188A (enExample) |
| AR (1) | AR121566A1 (enExample) |
| AU (1) | AU2021236340A1 (enExample) |
| BR (1) | BR112022018251A2 (enExample) |
| CA (1) | CA3171267A1 (enExample) |
| CL (1) | CL2022002479A1 (enExample) |
| CO (1) | CO2022014388A2 (enExample) |
| IL (1) | IL296075A (enExample) |
| MX (1) | MX2022011258A (enExample) |
| PE (1) | PE20230614A1 (enExample) |
| TW (1) | TW202200132A (enExample) |
| WO (1) | WO2021183934A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024530795A (ja) | 2021-09-01 | 2024-08-23 | スプリングワークス、セラピューティクス、インコーポレイテッド | ニロガセスタットの合成 |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| CN118302412A (zh) * | 2021-11-23 | 2024-07-05 | 梯瓦制药国际有限责任公司 | Nirogacestat盐的固态形式 |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US20230372301A1 (en) * | 2022-05-20 | 2023-11-23 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| AU2024231546A1 (en) * | 2023-03-09 | 2025-10-02 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of nirogacestat dihydrobromide, and preparation method therefor and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149855B2 (en) * | 2014-02-05 | 2018-12-11 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides |
| CN108025001A (zh) * | 2015-07-24 | 2018-05-11 | 安可初克公司 | 用于治疗免疫系统功能障碍的γ分泌酶调节剂 |
| WO2018151836A1 (en) * | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018201056A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| JP7050813B2 (ja) * | 2017-05-05 | 2022-04-08 | 華為技術有限公司 | 支援データ送信方法、デバイス、およびシステム |
| SG11202003427XA (en) * | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| WO2019143818A1 (en) * | 2018-01-17 | 2019-07-25 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| CN112203661A (zh) * | 2018-05-24 | 2021-01-08 | 艾雅拉制药公司 | 包含双氟烷基-1,4-苯并二氮杂*酮化合物与免疫治疗剂的组合物和其使用方法 |
| JP7398396B2 (ja) * | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Ｂｃｍａに対する結合分子及びその使用 |
| CN113924318B (zh) * | 2019-04-10 | 2025-06-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 |
| JP7608435B2 (ja) * | 2019-08-09 | 2025-01-06 | ファイザー・インク | （ｓ）－２－（（（ｓ）－６，８－ジフルオロ－１，２，３，４－テトラヒドロナフタレン－２－イル）アミノ）－ｎ－（１－（２－メチル－１－（ネオペンチルアミノ）プロパン－２－イル）－１ｈ－イミダゾール－４－イル）ペンタンアミドの固体状態形態およびその使用 |
-
2021
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
-
2022
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230009873A (ko) | 2023-01-17 |
| MX2022011258A (es) | 2023-01-11 |
| JP2025168430A (ja) | 2025-11-07 |
| PE20230614A1 (es) | 2023-04-14 |
| CA3171267A1 (en) | 2021-09-16 |
| TW202200132A (zh) | 2022-01-01 |
| US20230121547A1 (en) | 2023-04-20 |
| CN115916188A (zh) | 2023-04-04 |
| AU2021236340A1 (en) | 2022-09-29 |
| CL2022002479A1 (es) | 2023-08-18 |
| WO2021183934A1 (en) | 2021-09-16 |
| IL296075A (en) | 2022-11-01 |
| EP4132515A1 (en) | 2023-02-15 |
| JP2023517243A (ja) | 2023-04-24 |
| AR121566A1 (es) | 2022-06-15 |
| JP7781764B2 (ja) | 2025-12-08 |
| CO2022014388A2 (es) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018251A2 (pt) | Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma | |
| BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| NI201200030A (es) | Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas. | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| CY1123043T1 (el) | Συνδυαστικες θεραπειες για την αγωγη ανθεκτικων στη χημειοθεραπεια καρκινων | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| UY32359A (es) | Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento | |
| BR112015000660A2 (pt) | uso de uma terapia de primeira linha e uma terapia de segunda linha para tratamento de um paciente possuindo uma doença, desordem ou condição associada com uma expressão elevada de um antígeno de tumor, e de uma composição para reduzir ou evitar um efeito adverso associado com a administração de uma célula geneticamente modificada para expressar um car. | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112018071031A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| CY1122746T1 (el) | Ιατρικες αγωγες με βαση την αναμορελινη | |
| BR112018071023A2 (pt) | combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose | |
| CY1126041T1 (el) | Σκευασμα φαρμακου για χρηση στον αποτελεσματικο ελεγχο οξεος ή/και χρονιου πονου | |
| BR112023024501A2 (pt) | Método de tratamento da síndrome de down, método de melhora de eficácia de uma vacina e método de tratamento de câncer | |
| BR112022022599A2 (pt) | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma | |
| NI201500100A (es) | Mãtodos de tratamiento de la deficiencia de hierro con pirofosfato fãrrico soluble | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| CO2021008187A2 (es) | Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica | |
| CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) |